» Articles » PMID: 35490212

Expert Perspectives on the Introduction of Triple Artemisinin-based Combination Therapies (TACTs) in Southeast Asia: a Delphi Study

Overview
Publisher Biomed Central
Specialty Public Health
Date 2022 Apr 30
PMID 35490212
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Triple Artemisinin-based Combination Therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in Southeast Asia. However, the desirability, timing and practical feasibility of introducing TACTs in Southeast Asia is subject to debate. This study systematically assesses perspectives of malaria experts towards the introduction of TACTs as first-line treatment for uncomplicated falciparum malaria in Southeast Asia.

Methods: A two-round Delphi study was conducted. In the first round, 53 malaria experts answered open-ended questions on what they consider the most important advantages, disadvantages, and implementation barriers for introducing TACTs in Southeast Asia. In the second round, the expert panel rated the relevance of each statement on a 5-point Likert scale.

Results: Malaria experts identified 15 advantages, 15 disadvantages and 13 implementation barriers for introducing TACTs in Southeast Asia in the first round of data collection. In the second round, consensus was reached on 13 advantages (8 perceived as relevant, 5 as not-relevant), 12 disadvantages (10 relevant, 2 not-relevant), and 13 implementation barriers (all relevant). Advantages attributed highest relevance related to the clinical and epidemiological rationale of introducing TACTs. Disadvantages attributed highest relevance related to increased side-effects, unavailability of fixed-dose TACTs, and potential cost increases. Implementation barriers attributed highest relevance related to obtaining timely regulatory approval, timely availability of fixed-dose TACTs, and generating global policy support for introducing TACTs.

Conclusions: The study provides a structured oversight of malaria experts' perceptions on the major advantages, disadvantages and implementation challenges for introducing TACTs in Southeast Asia, over current practices of rotating ACTs when treatment failure is observed. The findings can benefit strategic decision making in the battle against drug-resistant malaria.

Citing Articles

Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion.

de Haan F, Amaratunga C, Thi V, Orng L, Vonglokham M, Quang T Malar J. 2023; 22(1):261.

PMID: 37674172 PMC: 10483751. DOI: 10.1186/s12936-023-04666-4.


A framework for stakeholder engagement in the adoption of new anti-malarial treatments in Africa: a case study of Nigeria.

Mokuolu O, Bolarinwa O, Opadiran O, Ameen H, Dhorda M, Cheah P Malar J. 2023; 22(1):185.

PMID: 37330469 PMC: 10276382. DOI: 10.1186/s12936-023-04622-2.


Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders' perspectives in Burkina Faso and Nigeria.

Tindana P, Guissou R, Bolarinwa O, Tou F, de Haan F, Dhorda M PLoS One. 2022; 17(9):e0273249.

PMID: 36083995 PMC: 9462557. DOI: 10.1371/journal.pone.0273249.

References
1.
de Haan F, Moors E, Dondorp A, Boon W . Market Formation in a Global Health Transition. Environ Innov Soc Transit. 2022; 40:40-59. PMC: 7612298. DOI: 10.1016/j.eist.2021.05.003. View

2.
Shawahna R . Using a mixed method to develop consensus-based aims, contents, intended learning outcomes, teaching, and evaluation methods for a course on epilepsy for postgraduate or continuing education in community health nursing programs. BMC Med Educ. 2021; 21(1):572. PMC: 8588674. DOI: 10.1186/s12909-021-03001-2. View

3.
Menard D, Dondorp A . Antimalarial Drug Resistance: A Threat to Malaria Elimination. Cold Spring Harb Perspect Med. 2017; 7(7). PMC: 5495053. DOI: 10.1101/cshperspect.a025619. View

4.
Fehr A, Thurmann P, Razum O . Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Serv Res. 2011; 11:312. PMC: 3228726. DOI: 10.1186/1472-6963-11-312. View

5.
Wells S, Diap G, Kiechel J . The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: case study. Malar J. 2013; 12:68. PMC: 3640935. DOI: 10.1186/1475-2875-12-68. View